Alpha Teknova Inc
teknova.comAlpha Teknova Inc (NASDAQ: TKNO) is a life sciences supply company that manufactures and sells custom, made-to-order biological reagents and media products used in drug research, development, and commercialization. Revenue comes from transactional product sales across three primary product types: pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation and resuspension. Teknova serves the life sciences market with both research-use-only (RUO) and GMP-grade formulations, positioning itself as an end-to-end supplier capable of scaling with customers from early development through commercial manufacturing. The company reported a net loss of $17.3 million in FY2025 and carried a senior secured term loan of up to $23.245 million under a credit agreement with MidCap Financial Trust as of March 3, 2025. Teknova does not pay dividends and intends to retain earnings to fund operations. The company has operated for more than two decades and supplies approximately 95 cell and gene therapy organizations as of the FY2025 10-K filed March 2, 2026.
Products & Services
Three primary product types per the FY2025 10-K: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation and resuspension. Products are offered in both RUO and GMP grades, with custom formulations produced to customer specifications typically within weeks of order receipt.
Revenue Model
Transactional product sales of custom and catalog biological reagents, culture media, and molecular biology products sold to life sciences customers across research and commercial manufacturing stages. No subscription or licensing model is described in the filing.
Customers & Markets
Life sciences customers engaged in drug research, development, and commercial manufacturing, including approximately 95 cell and gene therapy organizations (including mRNA) as of the FY2025 10-K. End markets include biopharmaceutical development, cell and gene therapy, mRNA therapeutics, antibody drug conjugates, and multi-specific antibodies. Customer spending is tied to their own R&D budgets, clinical trial activity, and FDA approval pipelines.
Geographic Exposure
The filing does not provide a geographic revenue breakdown. The company is subject to foreign data privacy laws, indicating some international customer activity, but no specific geographic revenue split is disclosed in the excerpts.
Financial Snapshot
Loading...
